Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
2.070
+0.140 (7.25%)
At close: Jan 17, 2025, 4:00 PM
2.100
+0.030 (1.45%)
Pre-market: Jan 21, 2025, 9:00 AM EST
Akebia Therapeutics Employees
Akebia Therapeutics had 167 employees as of December 31, 2023. The number of employees decreased by 38 or -18.54% compared to the previous year.
Employees
167
Change (1Y)
-38
Growth (1Y)
-18.54%
Revenue / Employee
$1,017,240
Profits / Employee
-$275,401
Market Cap
451.64M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
AKBA News
- 8 days ago - Akebia Therapeutics Announces Multiple Positive Business Updates - PRNewsWire
- 18 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 7 weeks ago - U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - PRNewsWire
- 2 months ago - Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - PRNewsWire
- 2 months ago - Q3 2024 Earnings: Hold Akebia Therapeutics - Seeking Alpha
- 2 months ago - Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - PRNewsWire
- 2 months ago - Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - PRNewsWire